BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33362981)

  • 1.
    Jensen SM; Kluxen FM; Streibig JC; Cedergreen N; Ritz C
    PeerJ; 2020; 8():e10557. PubMed ID: 33362981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model Uncertainty and Bayesian Model Averaged Benchmark Dose Estimation for Continuous Data.
    Shao K; Gift JS
    Risk Anal; 2014 Jan; 34(1):101-20. PubMed ID: 23758102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Recent Advances in Benchmark Dose Methodology.
    Jensen SM; Kluxen FM; Ritz C
    Risk Anal; 2019 Oct; 39(10):2295-2315. PubMed ID: 31046141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Web-Based System for Bayesian Benchmark Dose Estimation.
    Shao K; Shapiro AJ
    Environ Health Perspect; 2018 Jan; 126(1):017002. PubMed ID: 29329100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of three methods for integrating historical information for Bayesian model averaged benchmark dose estimation.
    Shao K
    Environ Toxicol Pharmacol; 2012 Sep; 34(2):288-296. PubMed ID: 22647377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmark dose modelling in regulatory ecotoxicology, a potential tool in pest management.
    Jensen SM; Kluxen FM; Ritz C
    Pest Manag Sci; 2022 May; 78(5):1772-1779. PubMed ID: 34908226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
    Davis JA; Gift JS; Zhao QJ
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A computational system for Bayesian benchmark dose estimation of genomic data in BBMD.
    Ji C; Weissmann A; Shao K
    Environ Int; 2022 Mar; 161():107135. PubMed ID: 35151117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the assumption of normality or log-normality for continuous response data critical for benchmark dose estimation?
    Shao K; Gift JS; Setzer RW
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):767-79. PubMed ID: 23954464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
    Izadi H; Grundy JE; Bose R
    Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the lower limit of benchmark dose confidence interval with no-observed-adverse-effect level by applying four different software for tumorigenicity testing of pesticides in Japan.
    Yasuhiko Y; Ishigami M; Machino S; Fujii T; Aoki M; Irie F; Kanda Y; Yoshida M
    Regul Toxicol Pharmacol; 2022 Aug; 133():105201. PubMed ID: 35691450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation.
    Wheeler MW; Bailer AJ
    Risk Anal; 2007 Jun; 27(3):659-70. PubMed ID: 17640214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benchmark dose modeling for epidemiological dose-response assessment using prospective cohort studies.
    De Pretis F; Zhou Y; Xun P; Shao K
    Risk Anal; 2024 Apr; 44(4):743-756. PubMed ID: 37496455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian model-averaged benchmark dose analysis via reparameterized quantal-response models.
    Fang Q; Piegorsch WW; Simmons SJ; Li X; Chen C; Wang Y
    Biometrics; 2015 Dec; 71(4):1168-75. PubMed ID: 26102570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update: use of the benchmark dose approach in risk assessment.
    ; Hardy A; Benford D; Halldorsson T; Jeger MJ; Knutsen KH; More S; Mortensen A; Naegeli H; Noteborn H; Ockleford C; Ricci A; Rychen G; Silano V; Solecki R; Turck D; Aerts M; Bodin L; Davis A; Edler L; Gundert-Remy U; Sand S; Slob W; Bottex B; Abrahantes JC; Marques DC; Kass G; Schlatter JR
    EFSA J; 2017 Jan; 15(1):e04658. PubMed ID: 32625254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benchmark Dose for Urinary Cadmium based on a Marker of Renal Dysfunction: A Meta-Analysis.
    Woo HD; Chiu WA; Jo S; Kim J
    PLoS One; 2015; 10(5):e0126680. PubMed ID: 25970611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Model Uncertainty on Benchmark Dose Estimation.
    West RW; Piegorsch WW; Peña EA; An L; Wu W; Wickens AA; Xiong H; Chen W
    Environmetrics; 2012 Dec; 23(8):706-716. PubMed ID: 23794799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonparametric Bayesian methods for benchmark dose estimation.
    Guha N; Roy A; Kopylev L; Fox J; Spassova M; White P
    Risk Anal; 2013 Sep; 33(9):1608-19. PubMed ID: 23339666
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.